Skip to content

A clinical study to evaluate the efficacy of GSH/Nut/S010 for female libido and fertility

A Randomised, Double Blind, Placebo Control clinical study to evaluate the efficacy of an herbal female libido enhancement product- GSH/Nut/S010 in women with low libido and a subgroup with primary infertility. - BIO/HGH/FSH/2026

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108320
Enrollment
80
Registered
2026-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hirehal Greenspace Herbs Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female aged more than or equal to 20 years and less than or equal to 55 years of age. 2.The study will recruiting females aged greater than or equal to 30 primarily. 3.BMI less than 30 kg/m2. 4.Currently in a stable, monogamous sexual relationship with partner with normal libido, with for at least 3 months. 5.Relationship Assessment Scale (RAS) score more than or equal to 15. 6.Estradiol levels less than 150 pg per ml at baseline. 7.Self-reported sexual dysfunction as indicated by FSFI score less than or equal to 20.0. 8.Perceived Stress Scale - 14 score more than 19 9.Individual literate enough to understand and comply with the study procedure. 10.Patients willing to provide written informed consent. Participants should additionally meet following criteria to be included in the cohort II of the study: 1. Females who have not achieved conception despite multiple attempts over the past six months. 2. Anti-mullerian Hormone more than 1.66 ng per ml.

Exclusion criteria

Exclusion criteria: 1.Have received androgen therapy at any time during the past 3 months. 2.Currently on Hormone replacement therapy. 3.Not in stable sexual relationship. 4.History of cancer at any time before study participation. 5.Diagnosed cases of Diabetes or Hypertension. 6.Females currently using any contraceptive method, including oral contraceptive pills (OCPs), intra-uterine devices (IUDs), implants, injectable contraceptives, transdermal patches, or vaginal rings. 7. Known cases of major psychiatric disorders which includes but is not limited to Bipolar disorder, Post-Traumatic Stress Disorder, Schizophrenia, Sexual Aversion Syndrome, psychosis etc. 8.History of early hysterectomy, oophorectomy, physiological conditions (Vaginismus). 9.History of cardiac, gastro, renal, or neurological disease. 10.History of HIV 1 or 2, Hepatitis B or C viruses, and syphilis. 11.History of alcoholism i.e. alcohol consumption greater than 2 units / day or10 units / week (one unit of alcohol equal to 50 ml spirit or 200 ml wine or 500ml beer). 12.History of smoking or Tobacco consumption. Participate.

Design outcomes

Primary

MeasureTime frame
Female Sexual Function Index (FSFI) Score. Timepoint: Baseline, Day 7, End of study

Secondary

MeasureTime frame
Sexual Desire Inventory-2 Female Sexual Distress Scale-Revised Pain Numeric Rating Scale Sexual Activity and Satisfaction Scale Sexual Quality of Life-Female Serum Estradiol levels Serum Progesterone levels Free Testosterone LevelsTimepoint: Baseline and End of Study;Cohort - II Rate of spontaneous pregnancyTimepoint: Throughout the study;Cohort - II Mid cycle Luteinizing Hormone (LH) surge Anti-M llerian Hormone (AMH)Timepoint: Baseline and End of Study

Countries

India

Contacts

Public ContactDr Shalini Srivastava

Bioaxion Innovation

dr.shalini@bioaxion.com9619477885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026